Numantec, a leading global developer, manufacturer and distributor of infusion medical devices, announced that the Private Equity business at Goldman Sachs Alternatives has agreed to acquire a majority stake in the Company from White Bridge Investments and other existing shareholders.

VIADANA, Italy - July 27, 2026 - Today, Numantec (the "Company"), a leading global developer, manufacturer and distributor of infusion medical devices, announced that the Private Equity business at Goldman Sachs Alternatives has entered into a definitive agreement to acquire a majority stake in the Company from White Bridge Investments and other existing shareholders.

Building on Numantec's track record of above-market growth, comprehensive product portfolio and track record in acquisitions, Goldman Sachs Alternatives is excited to partner with management on the Company's next stage of growth, focused on scaling its existing footprint and product portfolio, acquiring and developing new products, and expanding into new geographies and channels.

Headquartered in Viadana, Italy, Numantec develops, manufactures, and distributes infusion medical devices designed to enhance patient care and safety. Numantec employs approximately 600 people and operates seven state-of-the-art manufacturing facilities across Europe and the United States. The Company has delivered strong organic growth, supported by its comprehensive portfolio of innovative solutions serving highly recurring and non-discretionary clinical needs. Its diversified platform is well positioned to benefit from structural trends shaping the global medical consumables market.

Gabriele Giovanelli, Numantec CEO, said: "I am proud of what all the employees and management team at Numantec have achieved over the last several years. I am equally grateful to White Bridge Investments, who backed our vision from the start. Today I am genuinely excited about what comes next: in Goldman Sachs Alternatives we have found a partner who understands our sector, shares our ambition and brings the resources and international network to help us grow further. I cannot wait to get started."

Marco Pinciroli, Chairman and CEO of White Bridge Investments, commented: "It has been a privilege to partner with Numantec and its management team on this journey. The next chapter calls for greater scale and investment capacity, and in Goldman Sachs Alternatives the Company gains a partner with the healthcare track record and the global platform to deliver it - a team we have come to know well and appreciate over these past months. We wish everyone at Numantec every success in what comes next."

Michele Titi-Cappelli, Partner and Head of Southern Europe in Private Equity at Goldman Sachs Alternatives, said: "Numantec is a true Italian healthcare champion, built in Italy's renowned medtech manufacturing ecosystem, home to one of Europe's deepest clusters of medical-device innovation and manufacturing expertise. The Company has grown from its Italian roots into a diversified international platform with a direct presence in France, Germany, and the United States, serving customers globally."

Adam Dawson, Managing Director and Global Co-Head of Healthcare Private Equity at Goldman Sachs Alternatives, said: "Numantec provides critical, lifesaving medical devices to patients across homecare and hospital settings worldwide. The Company is well positioned at the intersection of several attractive trends in the medical devices sector, underpinning our conviction in the investment opportunity. We look forward to leveraging the Goldman Sachs Value Accelerator to support continued organic growth and accelerate the Company's expansion through strategic acquisitions, broadening its product portfolio, enhancing channel access, and strengthening its international footprint."

Gurmehar Grewal, Managing Director in Private Equity at Goldman Sachs Alternatives, said: "The Company's above-market organic growth reflects the quality of its products, breadth of portfolio, and ability to service customers and patients reliably every day. We look forward to partnering with Gabriele and the rest of the management team to support Numantec's ambitious global growth plans in its next chapter of growth."

Numantec was advised by J.P. Morgan (sole M&A advisor), Houlihan Lokey (debt advisor), White & Case, Giovannelli e Associati, BCG, Deloitte, Plante Moran, Gatti Pavesi Bianchi Ludovici Studio Associato, ERM, Intexo and Willis Towers Watson.

Goldman Sachs Alternatives was advised by Goldman Sachs International - Investment Banking Division, Bain, Deloitte, Latham & Watkins, Linklaters, LMS, A&O Shearman, QServe, Ramboll, and Aon.

Completion of the transaction is subject to customary regulatory approvals and is expected to close in Q4 2026.

About Numantec

Numantec is a global developer, manufacturer, and distributor of infusion medical devices, offering a comprehensive portfolio of innovative solutions designed to enhance patient care and safety. The Company serves the full infusion care pathway, from vascular access devices and injection systems to elastomeric and electronic pumps and pre-filled syringes. The Company employs approximately 600 people and operates seven state-of-the-art manufacturing facilities across Europe and the United States.

About Private Equity at Goldman Sachs Alternatives

Goldman Sachs (NYSE: GS) is one of the leading investors in alternatives globally, with over $645 billion in assets and more than 30 years of experience. The business invests in the full spectrum of alternatives including private equity, growth equity, venture capital, private credit, real estate, infrastructure, sustainability, and hedge funds. Clients access these solutions through direct strategies, customized partnerships, and open-architecture programs.

The business is driven by a focus on partnership and shared success with its clients, seeking to deliver long-term investment performance drawing on its global network and deep expertise across industries and markets.

The alternative investments platform is part of Goldman Sachs Asset Management, which delivers investment and advisory services across public and private markets for the world's leading institutions, financial advisors and individuals. Goldman Sachs has more than $4.0 trillion in assets under supervision globally as of June 30, 2026.

Established in 1986, Private Equity at Goldman Sachs Alternatives has invested over $75 billion since inception. The business combines a global network of relationships, unique insight across markets, industries and regions, and the worldwide resources of Goldman Sachs to build businesses and accelerate value creation across its portfolios.

Follow us on LinkedIn.

Media Contact

For Goldman Sachs Asset Management:
Joe Stein
[email protected]